Related Experiment Video

Updated: Jun 3, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Application of new drugs in chronic lymphocytic leukemia

Tadeusz Robak1

  • 1Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland.

Mediterranean Journal of Hematology and Infectious Diseases
|March 19, 2011
PubMed

Insights

New agents like monoclonal antibodies and Bcl-2 inhibitors show promise for treating chronic lymphocytic leukemia (CLL). Further research is needed for more effective and specific CLL therapies.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Chronic lymphocytic leukemia (CLL) treatment remains a challenge, with existing therapies offering only partial efficacy.
  • There is a continuous need for novel therapeutic strategies and more effective drugs for CLL management.

Purpose of the Study:

  • To review emerging therapeutic agents and strategies for chronic lymphocytic leukemia (CLL).
  • To highlight promising new treatments currently in preclinical and early clinical development for CLL.

Main Methods:

  • Review of preclinical studies and early clinical trials of novel CLL agents.
  • Identification and categorization of promising therapeutic classes including monoclonal antibodies, immunomodulating agents, purine analogs, and Bcl-2 inhibitors.

Main Results:

  • Several new agents demonstrate promise in preclinical and early clinical evaluations for CLL.
  • Targeted monoclonal antibodies (mAbs) against CD20, CD23, CD40, and CD37 are among the most promising.
  • Other agents like Oblimersen, flavopiridol, and lenalidomide are also under investigation.

Conclusions:

  • Emerging therapies offer potential advancements in CLL treatment.
  • Development of more specific and potent drugs is crucial for improving patient outcomes in CLL.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...